New study reveals sales potential of this large, expanding market
See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.
That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You see why the pain relievers industry and market will grow, as we predict.
In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 84 tables, 79 charts and three research interviews.
The following sections highlight what you discover in the report.
Prospects for submarkets and products
In addition to analyses of the overall world market, you see revenue forecasting of five world-level submarkets to 2023:
Neuropathic pain relievers
Treatments for migraines
Treatments for arthritis.
Also, you see how 29 leading drugs - including Oxycontin ER, Panadol, Lyrica and Zomig - can perform to 2023. Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. There, you find revenue forecasts and other data.
The work also breaks the overall world market into leading national markets.
Prospects for leading countries shown to 2023
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.
You discover revenue forecasts to 2023 for twelve national markets:
Germany, France, UK, Italy and Spain (EU5 nations)
This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.
Research and development activities
What's happening in the R&D pipeline for painkillers? You see developmental trends there:
Arthritic pain relievers.
Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.
Prominent issues affecting the pain treatment sector
Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:
Better treatment of acute and chronic pain worldwide, including cancer pain
Anticonvulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
Disease modifying anti-rheumatic drugs (DMARDs)
Biologics (e.g. monoclonal antibodies, MAbs) for rheumatoid arthritis (RA)
Reimbursement, regulations, patent expiries, generic competition and OTC switching.
You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.
Discussions of leading companies and prospects for market growth
What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues there from 2013 to 2023. The R&D pipeline is strong.
Overall world revenue for that market area will reach $68.0bn in 2013, our report forecasts. Ageing populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.
You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. This decade, many opportunities will arise.
Eight ways World Pain Relieving Drug Market 2013-2023 benefits you
In particular, then, our study gives you the following knowledge on painkilling drugs:
Forecasted revenues to 2023 for the overall world market and submarkets
Potential revenues of 29 leading products to 2023
Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil, Russia and Turkey
Assessment of companies - discussions of activities and outlooks
Review of R&D pipelines by treatment area - progress and trends
Opinions on the sector, including our research interviews with leaders in industry
Investigation of competition and opportunities influencing sales
Discussion of what stimulates and restrains the industry and market.
That work gives independent analyses from our primary and secondary research. You receive information found only in our report.
With our study, you find business intelligence to help you understand the future of that industry and market.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
Botox (Allergan): Market Analysis and Forecast, 2013-2023
Botox (onabotulinumtoxinA) is a protein and neurotoxin produced by the bacterium clostridium
botulinum. Botox is manufactured by Allergan Inc., and is used for cosmetic and therapeutic
purposes. Therapeutic uses include the treatment of certain neuromuscular disorders,
hyperhydrosis, prophylactic treatment of headaches in adults with chronic migraine and urinary
Botox was first approved by the US FDA in 1989 for the treatment of two eye muscle disorders,
strabismus and blepharospasm, making it the first botulinum toxin type A product approved in the
world. Since its first approval, Botox has been approved by regulatory authorities worldwide as a
treatment for approximately 25 unique indications in approximately 85 countries. Botox was first
approved for certain aesthetic uses in 2002.
Since the FDA's approval of Dysport, a competing product, the FDA has required that all botulinum
toxins marketed in the US include a boxed warning regarding the symptoms associated with the
spread of botulinum toxin beyond the injection site along with a corresponding risk evaluation and
mitigation strategies (REMS). However, apparently there has not been a confirmed case of spread
of toxin effect when Botox has been used at the recommended dose to treat chronic migraine,
reports also indicate.
American Academy of Pain Medicine
American Council for Headache Education
Australian New Zealand Clinical Trials Registry (ANZCTR)
Boston Millennia Partners
Centocor Ortho Biotech
CK Life Sciences
Dr. Reddy's Laboratories
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Frazier Healthcare Ventures
Human Genome Sciences
International Association for the Study of Pain
Johns Hopkins University
Johnson and Johnson (J&J)
Jyväskylä Central Hospital
Merck & Co.
Mitsubishi Tanabe Pharma
National Cancer Institute (NCI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE UK)
Procter & Gamble
Teva Pharmaceutical Industries
The Arthritis Foundation
The International Diabetes Federation (IDF)
The Neuropathy Association
The World Health Organization (WHO)
University of Queensland
US Census Bureau
US Society for Neuroscience
Valeant Pharmaceuticals International
Wyeth (now part of Pfizer)
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Departmental 1-5 Users
Electronic Access - Global Site License Fulfilled by Publisher